








Publisher Correction: XCR1⁺ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis

Aleksandra Deczkowska , Eyal David, Pierluigi Ramadori, Dominik Pfister, Michal Safran, Baoguo Li, Amir Giladi, Diego Adhemar Jaitin, Oren Barbov, Merav Cohen, Ido Yofe, Chamutal Gur, Shir Shlomi-Loubaton, Sandrine Henri , Yousuf Suhail, Mengjie Qiu, Shing Kam, Hila Hermon, Eylon Lahat, Gil Ben Yakov, Oranit Cohen-Ezra, Yana Davidov, Mariya Likhter, David Goitein, Susanne Roth, Achim Weber , Bernard Malissen , Assaf Weiner, Ziv Ben-Ari, Mathias Heikenwalder , Eran Elinav  and Ido Amit 

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-021-01344-3>, published online 20 May 2021.

In the version of this Article initially published, an electronic conversion error led to errors in the names of Michal Safran and Baoguo Li. Their names have been corrected in the online version of the article.

Published online: 12 January 2022

<https://doi.org/10.1038/s41591-021-01668-0>

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2021

Publisher Correction: Community evaluation of glycoproteomics informatics solutions reveals high-performance search strategies for serum glycopeptide analysis

Richard A. Koup, Ruben O. Donis, Peter B. Gilbert, Andrew W. Li, Najaf A. Shah and Christopher R. Houchens

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-021-01484-6>, published online 13 September 2021.






In the version of this article initially published, there was a composition error in Fig. 2, where point (2) duplicated point (5), whereas the text should have and now reads “(2) USG develops statistical plan for conducting correlates of protection analysis, coordinates sample selection with vaccine manufacturers.” The error has been corrected in the HTML and PDF versions of the article.

Published online: 12 January 2022

<https://doi.org/10.1038/s41591-021-01671-5>

This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022

Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jingao Li, Ying-Rui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Wan-Teck Lim , Wangjun Liao, Xiaohui He, Xiaozhong Chen, Zhigang Liu , Xianglin Yuan, Qi Li, Xiaoyan Lin, Shanghua Jing, Yanju Chen, Yin Lu, Ching-Yun Hsieh, Muh-Hwa Yang , Chia-Jui Yen, Jens Samol, Hui Feng, Sheng Yao, Patricia Keegan  and Rui-Hua Xu 

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-021-01444-0>, published online 2 August 2021.

In the version of this article initially published, there were textual errors in the abstract and main text. In the penultimate sentence of the abstract, the text “immune-related AEs (irAEs) (39.7 versus 18.9%) and grade ≥ 3 irAEs (7.5 versus 0.7%)” now replaces “immune-related AEs (39.7 versus 18.9%) and grade ≥ 3 infusion reactions (7.5 versus 0.7%).” In the third paragraph of the “Adverse events” subsection, first sentence, the text “infusion reactions (4.1 versus 4.2%) was similar in the two arms (Supplementary Tables 19–22). In contrast, irAEs as assessed by the investigator” now replaces “infusion reactions (irAEs) (4.1 versus 4.2%) was similar in the two arms (Supplementary Tables 19–22). In contrast, immune-related adverse events.” Further, in Table 2, bottom row “P value” entry, footnote “b” replaces “a”, and in the footnote legend, “a” replaces “*” and “b” replaces “a.” The changes have been made in the online version of the article.

Published online: 13 January 2022

<https://doi.org/10.1038/s41591-021-01673-3>

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2022